In systemic lupus erythematosus, which complement component deficiency is most strongly associated with increased risk of SLE development and is thought to impair clearance of immune complexes and apoptotic cells?

Explanation

## C1q Deficiency and SLE Pathogenesis **Key Point:** C1q deficiency is the strongest genetic risk factor for SLE development, present in nearly 90% of patients with hereditary C1q deficiency who develop SLE. C1q is the first component of the classical complement pathway and plays a crucial role in immune tolerance. ### Mechanism of C1q in Immune Homeostasis 1. **Clearance of Apoptotic Cells:** C1q binds to apoptotic cells and facilitates their rapid clearance by macrophages, preventing secondary necrosis and release of autoantigens. 2. **Immune Complex Handling:** C1q-mediated complement activation deposits C3b on immune complexes, marking them for clearance by follicular dendritic cells and preventing their deposition in tissues. 3. **B Cell Tolerance:** C1q is involved in suppressing autoreactive B cell responses through complement-dependent mechanisms. ### Comparative Analysis of Complement Deficiencies | Complement | SLE Risk | Mechanism | Clinical Feature | |-----------|----------|-----------|------------------| | **C1q** | Very high (90%) | Impaired apoptotic cell clearance + IC handling | Hereditary C1q deficiency → SLE | | **C4** | Moderate-high (75%) | Reduced IC solubilization; C4 polymorphisms | Partial C4 deficiency common in SLE | | **C3** | Moderate | Reduced opsonization; active SLE has low C3 | Reflects disease activity, not predisposition | | **C5** | Low | Preserved early complement steps | Neisseria meningitidis risk instead | **High-Yield:** C1q deficiency is the **strongest genetic predisposition** to SLE. Patients with hereditary C1q deficiency have a 90% lifetime risk of developing SLE or lupus-like disease. **Mnemonic:** **"C1q = Clearance Catastrophe"** — loss of C1q → impaired clearance of apoptotic debris and immune complexes → loss of tolerance → SLE. **Clinical Pearl:** In SLE patients, low C3 and C4 levels reflect **active disease** (especially nephritis), not genetic predisposition. These are markers of disease activity, not risk factors.